New studies also documented that Sorafenib treatment could up-control the expression of stem cells markers CD44 and CD47 and enrich the liver cancer stem cell populations from the tumor. Liver most cancers stem cells are refractory to Sorafenib and will hence account for the tumor remission right after prolonged Sorafenib https://crispr-library-screening09753.suomiblog.com/sirna-an-overview-39000983